[Bilateral breast bacterial cellulite secondary to Streptococcus agalactiae septicemia].
BACKGROUND
We report a case of group B streptococcal septicemia of digestive origin with secondary bilateral breast dermal-hypodermal localization.


METHODS
A 71 year-old woman with a past history of bilateral breast cancer treated by conservation therapy was hospitalized because of the sudden occurrence of two clearly delimited, inflammatory, dermal-hypodermal cutaneous plaques located on each breast, associated with fever (39 degrees C), 4 days after a colonoscopy. Further investigations eliminated carcinomatous mastitis and blood cultures were positive for group B beta-hemolytic streptococcus (Streptococcus agalactiae). Histological examination of a sigmoid polyp revealed a tubular adenocarcinoma.


CONCLUSIONS
We report the first documented case of secondary dermal-hypodermal bacterial skin infection (cellulitis) due to group B beta-hemolytic streptococcus. The occurrence after colonoscopy examination, chronology of clinical features, bilaterality and positive blood cultures are arguments in favor of the secondary nature of the skin infection process.
Conscience
I
I
Service de Dermatologie, CHU Robert Debré, Reims.
Perceau
G
G
Le Berruyer
P-Y
PY
Bernard
P
P
D000230:Adenocarcinoma / Q000150:complications / Q000601:surgery; D000368:Aged; D000658:Amoxicillin / Q000008:administration & dosage / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001941:Breast Diseases / Q000150:complications / Q000188:drug therapy / Q000209:etiology*; D002481:Cellulitis / Q000150:complications / Q000188:drug therapy / Q000209:etiology*; D019818:Clavulanic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D003111:Colonic Polyps / Q000175:diagnosis / Q000601:surgery; D003113:Colonoscopy; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008795:Metronidazole / Q000008:administration & dosage / Q000627:therapeutic use; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use; D018805:Sepsis / Q000150:complications* / Q000188:drug therapy; D012811:Sigmoid Neoplasms / Q000150:complications / Q000175:diagnosis / Q000601:surgery; D013290:Streptococcal Infections / Q000150:complications* / Q000188:drug therapy; D013292:Streptococcus agalactiae; D013997:Time Factors; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D008795:Metronidazole; D019818:Clavulanic Acid; D000658:Amoxicillin; D012293:Rifampin